Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab
- 专利权人:
- 发明人:
- 申请号：
- EP11305999.2
- 公开号：
- EP2550975A1
- 申请日:
- 2011.07.29
- 申请国别(地区):
- EP
- 年份:
- 2013
- 代理人:
- 摘要：
- A combination of an anti-CD19 maytansinoid immunoconjugate and rituximab is used for treating CD19+ CD20+ B-cell malignancies symptom, in particular Non-Hodgkins lymphoma.
- 来源网站：
- 中国工程科技知识中心
